ALGN Align Technology
Aligner franchise grown up: modest growth and margin repair, priced closer to fair than cheap.
The story
Align Technology is the dominant clear-aligner franchise (Invisalign plus iTero scanners), with a moat built on brand, a large orthodontist and GP network, and more than 20 million treated cases of data. It is now a maturing business: revenue growth has slowed to low single digits as consumer-financed elective demand stays weak and low-cost aligner rivals keep pressing on price. Margins are temporarily depressed by restructuring and mix, while the long-run opportunity in converting wires to aligners remains real but slower than bulls once assumed.
Growth of about 4%, slightly above the 2.6% five-year CAGR, reflects modest recovery in case starts and teen penetration, not a return to the hypergrowth era. The 20% target margin sits between today's charge-depressed 15.8% and the 2021 peak above 25%, consistent with cost actions but also with ongoing price pressure. Sales-to-capital of 1.6 is above the 1.02 trailing figure because incremental growth needs little new capital beyond scanners and plant capacity; that, together with a beta of 1.1 for consumer-discretionary sensitivity, narrows the large gap in the baseline model.
Value drivers
| Revenue growth (Y1) | 4.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 8y |
| Target operating margin | 20.0% |
| Years to target margin | 4 |
| Sales-to-capital | 1.60 |
| Beta | 1.10 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 10.2% |
| Terminal WACC | 9.8% |
Valuation bridge
| PV of explicit FCFF | 2.85B |
| PV of terminal value | 3.91B |
| Equity value | 7.70B |
| ÷ shares → per share | $108.42 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 4.31B | 4.0% | 16.8% | 507.65M | 103.49M | 404.16M | 366.66M |
| 2 | 4.47B | 3.9% | 17.9% | 560.47M | 103.78M | 456.69M | 375.87M |
| 3 | 4.64B | 3.7% | 18.9% | 615.77M | 103.79M | 511.97M | 382.28M |
| 4 | 4.80B | 3.6% | 20.0% | 673.47M | 103.51M | 569.96M | 386.09M |
| 5 | 4.97B | 3.4% | 20.0% | 696.56M | 102.92M | 593.64M | 364.82M |
| 6 | 5.13B | 3.3% | 20.0% | 719.44M | 102.01M | 617.43M | 344.24M |
| 7 | 5.29B | 3.1% | 20.0% | 742.05M | 100.78M | 641.27M | 324.36M |
| 8 | 5.45B | 3.0% | 20.0% | 764.32M | 99.22M | 665.09M | 305.20M |
Key risks
- Price competition from low-cost aligners and DSOs eroding Invisalign ASPs
- Weak consumer spending on elective procedures keeping case volumes flat
- Restructuring failing to lift margins back above 20%
Catalysts
- Recovery in case-start growth, especially teens and GP dentists
- Margin expansion from cost programs plus continued buybacks backed by $1.09B of net cash